ArticleJournal of cachexia, sarcopenia and muscle2025
Elevated Serum Gamma-Glutamyl Transferase as a Risk Factor for Frailty in Older Men: A Nationwide Population-Based Study.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frailty before chronic disease: multisystem physiological differences in middle-aged adults from the UK Biobank.GeroScience · 2026Article
- Elevated Serum Gamma-Glutamyl Transferase as a Risk Factor for Frailty in Older Men: A Nationwide Population-Based Study.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOxidative stress is a key driver of accelerated ageing, and gamma-glutamyl transferase (GGT), an essential enzyme involved in the metabolism of glutathione, a major antioxidant, plays a pivotal role in the generation of free radical species. This study aimed to explore the potential utility of circulating GGT as a biomarker of frailty, which reflects biological ageing and overall health status.
methodsThis cross-sectional, population-based study included 2526 community-dwelling adults aged 65 years and older, using data from the Korea National Health and Nutrition Examination Survey. Frailty was assessed using a deficit accumulation frailty index (FI) derived from 36 items encompassing physical, cognitive, psychological, and social domains. Participants were categorised as nonfrail (FI ≤ 0.15), prefrail (0.15 < FI ≤ 0.25), or frail (FI > 0.25). Serum GGT levels were determined using an enzymatic activity assay.
resultsAfter adjusting for potential confounders including age, body mass index, socioeconomic status, lifestyle factors, and medical history, serum GGT levels were 26.0% higher in frail men than in nonfrail men (p = 0.010). Amongst men, serum GGT concentrations were positively correlated with the FI (p = 0.001), and each standard deviation increase in serum GGT was associated with a 1.36-fold higher odds of frailty (p = 0.001). Additionally, older men in the highest GGT quartile exhibited a significantly higher FI and a 2.08-fold increased odds of frailty compared to those in the lowest quartile (p = 0.010 and p = 0.019, respectively). In women, however, no significant association was observed between serum GGT levels and frailty.
conclusionElevated serum GGT levels were significantly associated with frailty in older men, suggesting their potential as a biomarker of biological ageing. Nonetheless, the cross-sectional design precludes causal inference, and longitudinal studies are warranted to explore whether elevated GGT contributes to the onset or progression of frailty over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.